Advertisement

Hormones

, Volume 15, Issue 2, pp 271–276 | Cite as

Pasireotide for malignant insulinoma

  • Amit Tirosh
  • Salomon M. Stemmer
  • Evgeny Solomonov
  • Eldad Elnekave
  • Wolfgang Saeger
  • Yelena Ravkin
  • Kobi Nir
  • Yeela Talmor
  • Ilan Shimon
Case report

Abstract

Malignant insulinoma usually has a poor prognosis, as no efficient medical treatment is available. The somatostatin analogs octreotide and lanreotide have limited ability to control the hypoglycemic events. Pasireotide is a multi-receptor targeted somatostatin-analog with improved affinity for SSTR5. There is to date no reported treatment experience with this drug in such tumors. CASE DESCRIPTION: A 72-year-old patient with a G2 stage IV insulinoma, who underwent excision of the primary pancreatic tumor and multiple hepatic metastases, required further treatment for recurrent hypoglycemic events. The glycemic control achieved with pasireotide LAR was better compared with lanreotide and everolimus. However, none of these treatments showed tumor anti-proliferative effects. CONCLUSIONS: Pasireotide monthly injections achieved improved glycemic control in a patient with malignant insulinoma and recurrent hypoglycemic events compared with other medical treatments.

Key words

Hypoglycemia Insulinoma Neuroendocrine Pasireotide 

References

  1. 1.
    Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G, 2002 SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146: 707–716.CrossRefGoogle Scholar
  2. 2.
    Yao JC, Shah MH, Ito T, et al, 2011 Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364: 514–523.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Kulke MH, Bergsland EK, Yao JC, 2009 Glycemic control in patients with insulinoma treated with everolimus. N Engl J Med 360: 195–197.CrossRefGoogle Scholar
  4. 4.
    Kailey B, van de Bunt M, Cheley S, et al, 2012 SSTR2 is the functionally dominant somatostatin receptor in human pancreatic β- and α-cells. Am J Physiol Endocrinol Metab 303: E1107–E1116.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Zambre Y, Ling Z, Chen MC, et al, 1999 Inhibition of human pancreatic islet insulin release by receptor-selective somatostatin analogs directed to somatostatin receptor subtype 5. Biochem Pharmacol 57: 1159–1164.CrossRefGoogle Scholar
  6. 6.
    Colao A, Petersenn S, Newell-Price J, et al, 2012 A 12-month phase 3 study of pasireotide in Cushing’s disease. N Engl J Med 366: 914–924.CrossRefGoogle Scholar
  7. 7.
    Gadelha MR, Bronstein MD, Brue T, et al, 2014 Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial, lancet Diabetes Endocrinol 2: 875–884.CrossRefGoogle Scholar
  8. 8.
    Henry RR, Ciaraldi TP, Armstrong D, et al, 2013 Hyperglycemia associated with pasireotide: Results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab 98: 3446–3453.CrossRefGoogle Scholar
  9. 9.
    Hofland LJ, Lamberts SWJ, 2003 The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 24: 28–47.CrossRefGoogle Scholar
  10. 10.
    Portela-Gomes GM, Stridsberg M, Grimelius L, Rorstad O, Janson ET, 2007 Differential expression of the five somatostatin receptor subtypes in human benign and malignant insulinomas — predominance of receptor subtype 4. Endocr Pathol 18: 79–85.CrossRefGoogle Scholar

Copyright information

© Hellenic Endocrine Society 2016

Authors and Affiliations

  • Amit Tirosh
    • 1
    • 2
  • Salomon M. Stemmer
    • 2
    • 3
  • Evgeny Solomonov
    • 4
  • Eldad Elnekave
    • 3
  • Wolfgang Saeger
    • 5
  • Yelena Ravkin
    • 6
  • Kobi Nir
    • 7
  • Yeela Talmor
    • 8
  • Ilan Shimon
    • 1
    • 2
  1. 1.Endocrine InstituteRabin Medical CenterPetah TiqvaIsrael
  2. 2.Sackler Faculty of MedicineTel Aviv UniversityTel AvivIsrael
  3. 3.Institute of OncologyDavidoff Center, Rabin Medical CenterPetah TiqvaIsrael
  4. 4.SurgeryRivka Ziv medical centerSefadIsrael
  5. 5.Institute of NeuropathologyUniversity of HamburgHamburgGermany
  6. 6.Dan-Petah Tiqva districtClalit Health ServicesPetah TiqvaIsrael
  7. 7.Novartis Pharma ServicesPetah TiqvaIsrael
  8. 8.Internal Medicine FRabin Medical CenterPetah TiqvaIsrael

Personalised recommendations